Compare Simon Property Group Inc (SPG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs BIO-TECHNE Corp — how do they compare? Simon Property Group Inc trades at $227 (market cap $74.00B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Simon Property Group Inc is far larger — about 6.6× BIO-TECHNE Corp's market cap, and Simon Property Group Inc pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| SPG | TECH | |
|---|---|---|
Market Cap | $74.00B | $11.16B |
Sector | Real Estate | Health |
52-Week High | $228.70 | $72.12 |
52-Week Low | $160.68 | $43.31 |
Enterprise Value | $102.48B | $11.24B |
Dividend Yield | 3.86% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
